Tumor-infiltrating lymphocytes as easily accessible prognostic tool in adenocarcinoma of the colon
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.16991Keywords:
adenocarcinoma, colon cancer, overall survival, prognosis, tumor infiltrating lymphocytesAbstract
Summary. Aim: To determine the prognostic value of tumor-infiltrating lymphocytes (TILs) in colon adenocarcinomas. Materials and Methods: The study was performed on 180 paraffin blocks of operation material from patients diagnosed with adenocarcinoma of the colon, treated at the Kyiv City Oncology Center in 2013–2018. TILs were counted on histological slides stained with hematoxylin-eosin. By TILs count percentage in tumor slides, the samples were divided into three groups: 0–9% TILs (n = 65); 10–39% TILs (n = 79); and > 40% TILs (n = 36). Results: Kaplan — Meyer estimate showed that the difference in overall survival between groups was significant (p = 0.001). Multivariate Cox’s proportional hazard regression model analysis evidenced on significantly better overall survival rates in groups with moderate TILs percentage (hazard ratio 0.54, 95% CI 0.30–0.97, p = 0.042) and high TILs percentage (hazard ratio 0.36, 95% CI 0.13–0.99, p = 0.049), respectively, as compared with low TILs percentage group. Conclusion: TILs content can be considered as an independent prognostic factor for colon adenocarcinoma and used as an additional tool in routine practice of pathologists.
References
Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020; 70: 145–64. doi:10.3322/caac.21601
International Agency for Research on Cancer WHO; The Global Cancer Observatory — «Colon fact sheet» December 2020, https://gco.iarc.fr/today/data/factsheets/cancers/8-Colon-fact-sheet.pdf
Haghighi MM, Vahedi M, Mohebbi SR, et al. Comparison of survival between patients with hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancer. Asian Pac J Cancer Prev 2009; 10: 209–12.
Auclin E, Zaanan A, Vernerey D, et al. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol 2017; 28: 958–68. doi:10.1093/annonc/mdx030
Kang BW, Kim TW, Lee JL, et al. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol 2009 26(1): 32-7. doi:10.1007/s12032-008-9077-8
Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study [published correction appears in J Clin Oncol 2008; 26: 4697]. J Clin Oncol 2008; 26: 3523–9. doi:10.1200/JCO.2007.15.4138
Lee JJ, Chu E. The adjuvant treatment of stage III colon cancer: might less be more? Oncology (Williston Park) 2018; 32: 437–44.
Lin CC, Lai YL, Lin TC, et al. Clinicopathologic features and prognostic analysis of MSI-high colon cancer. Int J Colorectal Dis 2012; 27: 277–86. doi:10.1007/s00384-011-1341-2
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138: 2073–87.e3. doi:10.1053/j.gastro.2009.12.064
Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466–74. doi:10.1200/JCO.2009.23.3452
de Cuba EM, Snaebjornsson P, Heideman DA, et al. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. Int J Cancer 2016; 138: 1139–45. doi:10.1002/ijc.29855
Blair HA. Immunoscore®: A diagnostic assay for clinical management of colon cancer. Mol Diagn Ther 2020; 24: 365–70. doi:10.1007/s40291-020-00459-6
Galon J, Mlecnik B, Marliot F, et al. Validation of the immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: results of a worldwide consortium-based analysis of 1,336 patients. Colon Rectum 2016; 10: 197–9. doi:10.1007/s11725-016-0664-4
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182–8. doi:10.1111/his.13975
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259–71. doi:10.1093/annonc/mdu450
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–8. doi:10.1038/bmt.2012.244
Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375–9. doi:10.1038/35077241
Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 2018; 15: 366–81. doi:10.1038/s41571-018-0007-1
Idos GE, Kwok J, Bonthala N, et al. The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: A systematic review and meta-analysis. Sci Rep 2020; 10: 3360. doi:10.1038/s41598-020-60255-4
Zhang X, Quan F, Xu J, et al. Combination of multiple tumor-infiltrating immune cells predicts clinical outcome in colon cancer. Clin Immunol 2020; 215: 108412. doi: 10.1016/j.clim.2020.108412
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 2017; 14: 717–34. doi:10.1038/nrclinonc.2017.101
Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med 2011; 236: 567–79. doi:10.1258/ebm.2011.011007
Jakubowska K, Koda M, Kisielewski W, et al. Tumor-infiltrating lymphocytes in primary tumors of colorectal cancer and their metastases. Exp Ther Med 2019; 18: 4904–12. doi:10.3892/etm.2019.8146
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40–50. doi:10.1016/S1470-2045(17)30904-X
Pruneri G, Gray KP, Vingiani A, et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat 2016; 158: 323–31. doi:10.1007/s10549-016-3863-3
Blackley EF, Loi S. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Breast 2019; 48: S44–8. doi:10.1016/S0960-9776(19)31122-1
Skriver SK, Jensen MB, Knoop AS, et al. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Breast Cancer Res 2020; 22: 46. doi:10.1186/s13058-020-01285-8
Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020; 77: 181–5. doi:10.1111/his.14091
Matsutani S, Shibutani M, Maeda K, et al. Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer. Oncotarget 2018; 9: 15180–97. doi:10.18632/oncotarget.24612.
Iseki Y, Shibutani M, Maeda K, et al. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS One 2018; 13: e0192744. doi:10.1371/journal.pone.0192744
Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391: 2128–39. doi:10.1016/S0140-6736(18)30789-X
Weinberg RA, The Biology of Cancer. Second Edition. New York: Garland. Science 2014, 641–89.
Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 2007; 19: 339–47. doi:10.1016/j.coi.2007.04.007
Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 2015; 21: 5047–56. doi:10.1158/1078-0432.CCR-15-0685
Wouters MCA, Nelson BH. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin Cancer Res 2018; 24: 6125–35. doi:10.1158/1078-0432.CCR-18-1481
Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. Trends Immunol 2013; 34: 169–73. doi:10.1016/j.it.2012.10.007
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
